| CIN | Cervical Intraepithelial Neoplasia |
|---|---|
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
| CIN | central inhibition; cervical intraepithelial neoplasia; chronic interstitial nephritis |
| CIN1, | CIN I cervical intraepithelial neoplasia, grade 1 (mild dysplasia) |
| CIN | 2, CIN II cervical intraepithelial neoplasia, grade 2 (moderate-severe) |
| AIN | Anal intraepithelial neoplasia |
|---|---|
| CIN | Cervical Intraephithelial Neoplasia |
| CIN 3 | Cervical Intraepithelial Neoplasia grade 3 |
| CIN III | Cervical intraepithelial neoplasia grade III |
| GTN | Gestational trophoblastic neoplasia |
| neoplasia | <oncology, pathology> Literally new growth, usually refers to abnormal new growth and thus means the same as tumour, which may be benign or malignant. Unlike hyperplasia, neoplastic proliferation persists even in the absence of the original stimulus. Origin: Gr. Plassein = to form (18 Nov 1997) |
|---|
| cervical intraepithelial neoplasia | A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation. Origin: Gr. Plassein = to form (27 Sep 1997) |
|---|---|
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| prostatic intraepithelial neoplasia | A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer. (12 Dec 1998) |
| lobular neoplasia | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
| neoplasia |
the pathological process that results in the formation and growth of a tumor
출처: wordnet.princeton.edu/perl/webwn
|
|---|---|
| neoplasia |
Abnormal and uncontrolled cell growth.
출처: www.stjude.org/glossary
|
| neoplasia |
Abnormal growth and accumulation of cells. Neoplasias may be benign or malignant.
출처: www.peteducation.com/dict_alpha_listing.cfm
|
| neoplasia |
Abnormal new growth of cells.
출처: science.education.nih.gov/supplements/nih1/cancer/...
|
| neoplasia |
an abnormal cell growth that may progress to cancer.
출처: www.aegis.com/pubs/beta/1999/be990414.html
|
| neoplasia | the pathological process that results in the formation and growth of a tumor |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|